Stay updated with breaking news from Guidepoint Global. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimme
A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer.
Higginbotham will also keep his current responsibilities as senior vice-president for investor relations and financial planning and analysis while Foot
Human Resources and Workforce Management News
Drs. Thabele (Bay) Leslie-Mazwi; Ashutosh P. Jadhav; Justin M. Cappuzzo; Elad I. Levy; Waleed Brinjikji; & Demi Dawkins each ponder what the next breakthrough in acute ischemic stroke therapy should be, with responses ranging from technology & technique...